ERC Consolidator Grant · 2024
The obesity epidemic has caused a surge of metabolic-dysfunction associated steatotic liver disease (MASLD), an important cause of morbidity and mortality. This also leads to other liver diseases presenting with steatotic (fatty) liver as a “second hit”, with unpredictable impact on clinical outcome. In the present project, I will use the co-existence of two different liver diseases to study how the gut microbiome interacts with steatosis and autoimmunity. Both MASLD and primary sclerosing cholangitis (PSC), an autoimmune disease of the bile ducts, are more common in inflammatory bowel disease (IBD) than in the population, suggesting they are driven by gut microbial activity (gut signals).…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.